@JulieM
Q3 in any other country outside Australia in retail is July August September - as they are referring to the United States - i would suspect that Q3 releates to that time period - and not the Australian Q3 accounting period - i would check with the company if they are referring to Q3 ( australian acountancy period) or Q3 (USA retail period ) The realtek chipset has been available for over 5 years in its current format - every wireless earbud manufacturer pretty much uses it, apart from Nuheara - as that chipset was the smallest on the market - allowing all the other manufactuers to shrink their earbud size , which if Nuhear had chosen that chip initially, it would have allowed NUH the opportunity to shrink their earbud size down to a size level that is more consumer friendly and at a size comparable with the other earbud manufacturers. The realtek deal is interesting BUT with the caveat that realtek sells its chipset solutions in modules to manufacturers ( IE you can add on or remove items you do not want when you come to specify a chipset for a new earbud design ) so the uptake would be from manufacturing companies that want to embed the Nuheara solution into the chipset, so in terms of money coming in from that deal, it would all depend on which companies wish to utilise it on their reference designs for future earbud/hearing projects, and as these project take primarily between 1 to two years to come to fruition, it is not a short term money fix BUT could be good longterm.The biggest problem with Nuheara is that customers with hearing problems, are similar to people with medical problems. If you have a medical problem, you go to a Doctor, if you have a hearing problem, you go to an audiologist. You would have to change peoples mindsets in order for mass sales to take off, which is not easy. The other issue is that people who have mild to mid hearing loss, dont actually realise ( unless they go to an audiologist) that they have mild to mid hearing loss, therefore until they realise that, they will not go out looking for an OTC product, as they dont realise they need one. Coupled with that, is the issue that audiologists wil always sell the hearing aid to a mild to mid hearing loss patient, as thats where they make their money, in terms of the initial sale, and in terms of follow up sales. Thye would not sell an earbud when they can sell a hearing aid for ten times the profitability and ongoing tuning fees etc.On the pay upfront or on delivery, that is a fantasy in the retail and audiology world UNLESS they are doing OEM projects for another manufcturer, on which that manufcturer may be on those terms. BUT in retail and audiology, the fastest you would ever get paid is on 3o days but normally they would be on 60 or 90 day terms, most likely with an undertaking that if old stock remains after 90 days, it would be taken back and credited against any outstanding invoice money owed in that quarter.Nuheara is great in concept, but very hard to implement and execute due to the above reasoning. The realtek deal could be extremley good IF manufacturers choose to embed the hearing software into their design, that is not a given, but an IF. Always better to keep the conversation real in terms of expectations, as all the above has to be taken into consideration and then you take a view. It is a long term stock IF they can keep going ( which one hopes they can ) which may come good given time, but i do not beleive it will be in 2023, but mid 2024 when we will find out if the company is going to be a success or not, as by then you will see the actual physical sales and realtek chipset agemments come into play and into the accounts.
(20min delay)